• Clover Health Investments (NasdaqGS:CLOV) reports very large year over year growth in third party clinician adoption of its Counterpart Health platform, above 450%.
• Counterpart Health is shifting from an internal tool to a SaaS platform used by external payors and providers.
• The platform has achieved the #1 HEDIS score nationally for a PPO Medicare Advantage plan.

Clover Health, trading at around $2.0, has seen pressure on the share price over multiple timeframes, with a 17.0% decline year to date and a 46.2% decline over the past year. That sits alongside a much stronger 3 year return of 96.1%, highlighting how volatile NasdaqGS:CLOV has been for investors who bought at different points.

In that context, the recent traction for Counterpart Health as a third party SaaS product provides a fresh development to watch that is separate from the core insurance book. As more external payors and providers use the platform and HEDIS performance remains strong, investors may focus more closely on how much of Clover Health's overall story is tied to software revenue and margin potential versus traditional Medicare Advantage economics.

Stay updated on the most important news stories for Clover Health Investments by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Clover Health Investments.

The sharp pickup in third party use of Counterpart Health comes at an important time for Clover Health. The core insurance business is still loss making, with a Q4 2025 net loss of US$49.32 million and a full year loss of US$85.55 million, even as revenue reached US$1.92b. Management is now targeting 2026 revenue of US$2.81b to US$2.92b and GAAP net income between breakeven and US$20 million. In that context, turning Counterpart from an internal tool into a SaaS platform gives Clover a way to pursue software and services revenue that is not limited to its own Medicare Advantage membership. Rapid growth in external clinicians on the platform and top ranked HEDIS quality scores may help Clover pitch Counterpart Health to other payors that are also trying to manage medical costs and quality, similar to how larger insurers such as UnitedHealth, Humana and CVS Health use their own tech stacks. The key question for investors is how quickly SaaS and tech enabled services can become material alongside the insurance book, and whether they can support the push toward profitability while the company continues to invest in growth.

How This Fits Into The Clover Health Investments Narrative

• The rapid adoption of Counterpart Health by third party clinicians directly supports the narrative that Clover can use technology driven care models to create new revenue streams beyond its Medicare Advantage plans.
• At the same time, the company is still reporting GAAP net losses, which challenges the assumption that technology and membership growth will smoothly translate into higher, more stable margins.
• The narrative focuses heavily on Clover Assistant and Medicare Advantage membership growth, while this latest Counterpart Health traction highlights a SaaS opportunity that may not yet be fully reflected in long term expectations.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Clover Health Investments to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Clover is guiding to GAAP net income of only US$0 million to US$20 million in 2026, so any setback in medical cost trends or SaaS monetization could leave profitability out of reach.
• ⚠️ The company has a good financial health score but still faces a major risk from having less than one year of cash runway, which limits room for missteps as it scales Counterpart Health.
• 🎁 Very large growth in third party clinicians using Counterpart Health, combined with a #1 national HEDIS score, gives Clover a referenceable proof point when pitching the platform to other payors and providers.
• 🎁 Management is guiding to strong revenue expansion to US$2.81b to US$2.92b and expects 2026 to be the first year of GAAP net income profitability, suggesting that operating leverage from both insurance and SaaS could begin to show through.

What To Watch Going Forward

From here, it will be important to watch how quickly Counterpart Health starts to contribute visible SaaS and tech enabled services revenue, and whether that revenue carries higher margins than the insurance book. Investors may also focus on updates to clinician and customer counts on the platform, evidence that quality metrics such as HEDIS scores are sustained as the user base grows, and any new partnerships with external payors. On the financial side, tracking quarterly progress toward the 2026 targets for US$2.81b to US$2.92b in revenue and breakeven to US$20 million in GAAP net income will help show whether the combined insurance and software model is moving toward the profitability and scale the company is aiming for.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Clover Health Investments, head to the community page for Clover Health Investments to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.